Biogen completed the acquisition of Human Immunology Biosciences for $1.8bn.

Biogen, a biotechnology company, completed the acquisition of Human Immunology Biosciences, a biotechnology company focused on developing therapies for immune-mediated diseases, for $1.8bn. “With its deep development and commercialization capabilities, Biogen is in a position to accelerate the development of new medicines, including felzartamab, for patients with severe immune-mediated diseases. We are excited to combine the HI-Bio team’s expertise with Biogen’s global footprint,” Travis Murdoch, HI-Bio CEO.